骨髓增生异常综合征患者RAS基因突变的分子特征及预后价值
该回顾性研究对776例新诊断原发MDS患者行112基因靶向测序,发现RAS突变占6.7%,多为亚克隆突变,与MDS-EB及较高危IPSS-R相关。NRAS突变单因素与更短OS相关,但多因素校正后失去显著性,仅PTPN11为独立不良预后因素。
要点
- RAS突变见于6.7%的MDS患者,以NRAS为主(4.9%),多位于第12、13及61号密码子。
- RAS突变常为亚克隆,与PTPN11、FLT3、U2AF1、RUNX1、WT1、ETV6及NPM1突变共现。
- RAS突变患者MDS-EB比例及IPSS-R较高危比例更高,但多因素校正后NRAS非独立预后因素。
核心结论
- RAS基因突变常作为亚克隆发生在MDS疾病晚期,常与信号转导及转录因子相关基因突变伴随发生。
- RAS通路相关的PTPN11突变在MDS中为独立不良预后因素。
研究设计与样本
- 回顾性研究纳入2011年12月至2018年12月新诊断且完成二代测序的原发MDS患者776例。
- 采用112基因靶向测序检测RAS突变,分析其分子特征、共现/互斥关系及对总生存的影响。
主要发现
- 52例(6.7%)伴RAS突变:NRAS 38例(4.9%)、KRAS 18例(2.3%)、NRAS与KRAS共存4例(0.5%)。
- 全部NRAS突变及65%的KRAS突变位于第12、13及61号密码子。
- RAS突变与PTPN11、FLT3、U2AF1、RUNX1、WT1、ETV6及NPM1突变呈显著正相关(Q<0.05)。
- 约80%的RAS突变在携带至少两种不同突变的患者中为亚克隆病变。
- RAS突变患者MDS-EB比例82.7% vs 35.2%(P<0.001),IPSS-R较高危比例71.1% vs 37.9%(P<0.001)。
关键数值与推荐
- RAS突变患者WBC 4.33(0.98~20.42)×10^9/L vs 2.71(0.61~21.17)×10^9/L,P<0.001。
- RAS突变患者ANC 2.13(0.18~17.37)×10^9/L vs 1.12(0~16.00)×10^9/L,P<0.001。
- RAS突变患者血小板48(2~430)×10^9/L vs 62(2~694)×10^9/L,P=0.048。
- RAS突变患者骨髓原始细胞比例7% vs 2%(P<0.001)。
- 单因素分析NRAS突变与更短OS显著相关(P=0.011),多因素校正后失去显著性;仅PTPN11及SETBP1为独立不良OS因素。
临床怎么用
- 对MDS患者行RAS通路基因检测有助于识别高危亚群,尤其应关注PTPN11突变以进行预后分层。
局限性
- 为单中心回顾性研究,RAS突变亚组样本量较小(52例)。
- NRAS突变对OS的影响在多因素模型中不显著,提示其预后价值受其他因素混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes (MDS) . Methods: 112-gene targeted sequencing was conducted to detect RAS mutations in 776 patients with newly diagnosed primary MDS from December 2011 to December 2018. The mutual exclusivity and co-occurrence in gene mutations and clonal architecture were explored. Moreover, the prognostic significance of RAS mutations in MDS was analyzed. Results: RAS gene mutations were found in 52 (6.7% ) cases, 38 (4.9% ) of whom harbored NRAS mutation, 18 (2.3% ) KRAS mutation, and 4 (0.5% ) both NRAS and KRAS mutations. All the NRAS mutations and 65% of the KRAS mutations were located in codons 12, 13, and 61. PTPN11, FLT3, U2AF1, RUNX1, WT1, ETV6, and NPM1 mutations were enriched in patients with RAS mutations (Q<0.05) . Around 80% of RAS mutations represented subclonal lesions in patients who harbored at least two different mutations. Patients with RAS mutations were more frequently diagnosed with MDS with excess blast (MDS-EB) (82.7% vs. 35.2% , P<0.001) and had higher levels of white blood cell count (4.33×10(9)/L vs. 2.71×10(9)/L, P<0.001) , neutrophil absolute count (2.13×10(9)/L vs. 1.12×10(9)/L, P<0.001) , and bone marrow blast percentage (7% vs. 2% , P<0.001) but lower levels of platelet count (48×10(9)/L vs. 62×10(9)/L, P=0.048) . RAS mutations were correlated with higher-risk categories in the Revised International Prognostic Scoring System (IPSS-R) (71.1% vs. 37.9% , P<0.001) . The median overall survival of patients with NRAS mutations was shorter than the others (P=0.011) , while the significance was lost in the multivariable model. Conclusion: RAS gene mutations always occurred in the late-stage MDS and co-occurred with other signal transduction- and transcription factor-related gene mutations. PTPN11, a RAS pathway-related gene, is an independent poor prognostic factor in MDS patients. 目的: 探讨骨髓增生异常综合征(MDS)RAS基因突变的分子学特征及其对预后的影响。 方法: 收集2011年12月至2018年12月新诊断且完成二代测序的776例MDS患者病例资料,回顾性分析RAS基因突变患者的临床及分子学特征,并比较不同突变状态对总生存(OS)的影响。 结果: 共52例(6.7%)患者伴有RAS基因突变,NRAS突变38例(4.9%),KRAS突变18例(2.3%),4例(0.5%)同时伴NRAS及KRAS突变,全部NRAS突变及65%的KRAS突变位于第12、13及61号密码子。RAS基因突变与PTPN11、FLT3、U2AF1、RUNX1、WT1、ETV6及NPM1突变呈显著正相关(Q<0.05),且常为亚克隆突变。伴RAS基因突变的患者中诊断为MDS伴原始细胞增多(MDS-EB)的比例(82.7%)明显高于无RAS突变患者(35.2%)(P<0.001)。与无RAS基因突变患者相比,伴RAS基因突变患者的外周血白细胞水平和中性粒细胞水平明显升高[WBC:4.33(0.98~20.42)×10(9)/L对2.71(0.61~21.17)×10(9)/L,P<0.001;ANC:2.13(0.18~17.37)×10(9)/L对1.12(0~16.00)×10(9)/L,P<0.001],血小板水平明显减低[48(2~430)×10(9)/L对62(2~694)×10(9)/L,P=0.048],骨髓粒系比例有升高的趋势(47%对40%,P=0.085),骨髓原始细胞比例明显升高(7%对2%,P<0.001)。按照修订的国际预后积分系统(IPSS-R)进行预后分层,RAS基因突变患者中较高危分组(高危和极高危组)的比例显著增高(71.1%对37.9%,P<0.001)。单因素分析中,NRAS突变与更短的OS显著相关(P=0.011),经多因素校正后,NRAS突变对OS的影响失去显著性,突变基因中仅PTPN11及SETBP1为独立的不良OS因素。 结论: RAS基因突变常作为亚克隆发生在MDS疾病晚期且常与转录因子及信号转导相关的突变伴随发生。RAS通路相关的PTPN11突变在MDS中为独立不良预后因素。.
引用
- Huang HJ, Li B, Qin TJ, et al. [Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33113603. doi:10.3760/cma.j.issn.0253-2727.2020.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。